SK31999A3 - Use of sibutramine analogues to prevent the development of diabetes - Google Patents

Use of sibutramine analogues to prevent the development of diabetes Download PDF

Info

Publication number
SK31999A3
SK31999A3 SK319-99A SK31999A SK31999A3 SK 31999 A3 SK31999 A3 SK 31999A3 SK 31999 A SK31999 A SK 31999A SK 31999 A3 SK31999 A3 SK 31999A3
Authority
SK
Slovakia
Prior art keywords
insulin
formula
compound
medicament
manufacture
Prior art date
Application number
SK319-99A
Other languages
English (en)
Slovak (sk)
Inventor
Clifford J Bailey
Robert B Jones
Helen C Jackson
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of SK31999A3 publication Critical patent/SK31999A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
SK319-99A 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes SK31999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (1)

Publication Number Publication Date
SK31999A3 true SK31999A3 (en) 1999-12-10

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
SK319-99A SK31999A3 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (uk)
EP (1) EP0927028A1 (uk)
JP (1) JP2001503737A (uk)
KR (1) KR20000048501A (uk)
CN (1) CN1237905A (uk)
AU (1) AU724488B2 (uk)
BG (1) BG64473B1 (uk)
BR (1) BR9711517A (uk)
CA (1) CA2266401C (uk)
CZ (1) CZ93699A3 (uk)
GB (1) GB9619757D0 (uk)
HR (1) HRP970505A2 (uk)
HU (1) HUP9904026A3 (uk)
ID (1) ID18320A (uk)
IL (1) IL128850A (uk)
MY (1) MY116150A (uk)
NO (1) NO991358D0 (uk)
NZ (1) NZ334580A (uk)
PL (1) PL332305A1 (uk)
RU (1) RU2245709C2 (uk)
SK (1) SK31999A3 (uk)
TR (1) TR199900618T2 (uk)
TW (1) TW580385B (uk)
UA (1) UA64726C2 (uk)
WO (1) WO1998011884A1 (uk)
ZA (1) ZA978450B (uk)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
KR20010043455A (ko) * 1998-06-30 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료용 약학적 조성물
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CZ20011629A3 (cs) * 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
EP1185232A1 (en) 1999-06-01 2002-03-13 University Of Texas Southwestern Medical Center Method of treating hair loss using sulfonyl thyromimetic compounds
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
WO2004030663A1 (en) * 2002-10-05 2004-04-15 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
TW200517127A (en) * 2003-08-07 2005-06-01 Sb Pharmco Inc Novel composition
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
GEP20084570B (en) * 2003-10-31 2008-12-25 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
CN101394847B (zh) 2006-01-06 2017-05-24 塞普拉柯公司 作为单胺重摄取抑制剂的环烷基胺类
AU2007296074B2 (en) 2006-09-15 2012-07-12 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
EP2083867A1 (en) * 2006-11-22 2009-08-05 SK Chemicals, Co., Ltd. Inclusion complex of sibutramine and beta-cyclodextrin
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2603600B1 (en) 2010-08-13 2018-11-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
CA2858837C (en) 2011-12-30 2022-08-30 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
AU2013221432B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CN112245565A (zh) 2014-09-24 2021-01-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
US6174925B1 (en) 2001-01-16
RU2245709C2 (ru) 2005-02-10
MY116150A (en) 2003-11-28
IL128850A0 (en) 2000-01-31
TR199900618T2 (xx) 1999-06-21
UA64726C2 (uk) 2004-03-15
HUP9904026A2 (hu) 2000-05-28
US6617360B1 (en) 2003-09-09
NO991358L (no) 1999-03-19
ZA978450B (en) 1999-03-19
US20040077730A1 (en) 2004-04-22
GB9619757D0 (en) 1996-11-06
TW580385B (en) 2004-03-21
CZ93699A3 (cs) 1999-08-11
ID18320A (id) 1998-03-26
BG103277A (en) 2000-01-31
BR9711517A (pt) 1999-08-24
NZ334580A (en) 2000-09-29
AU724488B2 (en) 2000-09-21
CA2266401A1 (en) 1998-03-26
HUP9904026A3 (en) 2000-07-28
CA2266401C (en) 2007-01-30
HRP970505A2 (en) 1998-08-31
WO1998011884A1 (en) 1998-03-26
EP0927028A1 (en) 1999-07-07
NO991358D0 (no) 1999-03-19
AU4774097A (en) 1998-04-14
CN1237905A (zh) 1999-12-08
KR20000048501A (ko) 2000-07-25
PL332305A1 (en) 1999-08-30
IL128850A (en) 2003-07-31
JP2001503737A (ja) 2001-03-21
BG64473B1 (bg) 2005-04-30

Similar Documents

Publication Publication Date Title
US6174925B1 (en) Use of sibutramine analogues to prevent the development of diabetes
US6187820B1 (en) Medical treatment to improve lipid levels
US6365633B1 (en) Method of treating eating disorders
WO2001062341A2 (en) Combination product for the treatment of obesity
EP1007023B1 (en) 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine derivatives for lowering the uric level in humans
BG104568A (bg) Фармацевтичен състав, съдържащ сибутрамин и орлистат
US6376552B1 (en) Treatment of gallstones
US6372798B1 (en) Treatment of hyperactivity disorders
US6372797B1 (en) Treatment of menstrual function
US6441046B1 (en) Control of metabolism
US6403650B1 (en) Treatment of pulmonary hypertension
MXPA99002598A (en) Use of sibutramine analogues to prevent the development of diabetes
US6288125B1 (en) Treatment of hiatial hernia
US6433020B1 (en) Treatment of cardiovascular disease
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat
MXPA99002633A (en) Use of sibutramine analogues to lower lipid levels